Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

Sella, T; Zheng, Y; Tayob, N; Ruddy, KJ; Freedman, RA; Dang, C; Yardley, D; Isakoff, SJ; Valero, V; DeMeo, M; Burstein, HJ; Winer, EP; Wolff, AC; Krop, I; Partridge, AH; Tolaney, SM

Tolaney, SM (通讯作者)，Dana Farber Canc Inst, Boston, MA 02115 USA.;Tolaney, SM (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.

NPJ BREAST CANCER, 2022; 8 (1):

Abstract

In the ATEMPT trial, adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel plus trastuzumab (TH) for stage I HER2-positive breast cancer impro......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索